Skip to content

Virtual Webinars

Nov 12, 2026

Ask the Expert | A Year in Review for Uveal Melanoma: Recent Advances and Future Directions  

Register Now

Date and Time

Nov 12, 2026 · 7:00 - 8:00 EDT ET

Virtual Event

Zoom

Register Now

About This Event

With new data shared at major meetings like European Society for Medical Oncology (ESMO), along with a growing number of clinical trials, this year has given uveal melanoma (UM) patients and families more reasons for hope than ever before.

 

Join us for an informative and interactive webinar with uveal melanoma expert Marlana Orloff, MD, who will walk through the year’s most important UM advances, what they mean for patients today and where research is headed next, including new opportunities for treatment earlier in the course of the disease. Following the presentation, you will have the chance to ask your own questions directly to the expert.
 

We would like to thank IDEAYA Biosciences for generously sponsoring this webinar. Register today to learn more! 

Speakers:

Marlana Orloff, MD
Dr. Marlana Orloff is a medical oncologist and clinical researcher at Thomas Jefferson University and the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania. She specializes in melanoma, with particular expertise in uveal melanoma and other rare melanoma subtypes. As Co-Director of the Melanoma Research Institute and Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, Dr. Orloff is dedicated to advancing treatment options for patients with these challenging malignancies.

 

Through her research, academic collaborations, and commitment to specialized cancer care, she contributes to the evolving understanding of melanoma biology and the development of innovative therapeutic strategies. She is widely published in the field of melanoma research and has authored numerous peer-reviewed publications. Dr. Orloff is committed to translating scientific advances into meaningful improvements in patient outcomes and expanding treatment opportunities for individuals affected by rare and difficult-to-treat cancers.